Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309
Saluda Medical Appoints Laureen DeBuono to Board of Directors 
Halma acquires IZI Medical Products for £138 Million
OneStep Innovates with New Approach to Fall Risk Assessment